The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis

The FLT3-ITD mutation is one of the most common rearrangements in acute myeloid leukemia (AML), and is particularly associated with poor prognosis and recurrent development of resistance. In 2017, the FLT3 tyrosine kinase inhibitor (TKI) midostaurin was approved for use in combination with standard